MedTrace Logo

LTX-109 as Treatment for Hidradenitis Suppurativa

NCT04756336 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-08-30

No results posted yet for this study

Summary

An Open label Phase II//proof of concept-study to demonstrate if percutaneous application of LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify clinical response to intervention, as well to identify if covariates such as age, disease duration, smoking state and BMI influence patient reported measures.

Conditions

Interventions

DRUG

LTX-109 gel, 3% w/w

The drug is applied to affected lesions according to treatment regimen

Sponsors & Collaborators

  • University Hospital of North Norway

    collaborator OTHER

  • Pharma Holdings AS

    lead INDUSTRY

Principal Investigators

  • Øystein Grimstad, Phd., MD · University Hospital of North Norway

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2021-07-01
Completion
2021-07-01

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756336 on ClinicalTrials.gov